The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Dr Reddy's, Zydus Lifesciences,... Feb 19, 2025 19:23 Cipla Q3 Profit Surges 49% to Rs 1,571 Crore Cipla's net profit for Q3 FY25 jumped 49% to Rs 1,571 crore, driven by growth across markets. Revenue ...

Cipla Ltd is one of the leading pharmaceutical companies in India. The Company is in the business of manufacturing developing and marketing wide range of branded and generic formulations and Active ...

Cipla Q3 results review: The shares of the third largest pharmaceutical firm Cipla rose 2.44 per cent at Rs 1,454.20 a piece on the BSE intraday after the company delivered a solid quarterly earnings ...

Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses.

Return on investment - most recent fiscal year 16.16 ...

Drug major Cipla reported a 49% year-on-year jump in its December quarter consolidated net profit, reaching Rs 1,571 crore, compared to Rs 1,056 crore in the same period last year. The profit after ...

Cipla Ltd.'s consolidated net profit rose 49% year-on-year in the third quarter of the current financial year, beating analysts' estimates by a substantial margin. The drugmaker posted a consolidated ...

Cipla's stock is priced at Rs 1473.75, showing an increase of 1.7% today, with a monthly return of 2.73%. Cipla's shares are currently priced at Rs 1477.55, reflecting a daily increase of 1.96%. The ...

Shares of drugmaker Cipla Ltd. surged to the day's high, gaining as much as 4% after the company's December quarter results. The results were a beat across parameters.

In limited trials, tetracycline mouth rinse, betamethasone gel, beclomethasone spray, and amlexanox significantly reduced ulcer duration and pain. In contrast, chlorhexidine mouthwash had no ...

HYDERABAD/BENGALURU (Reuters) -Cipla, one of India's largest drugmakers by sales, reported a bigger-than-expected third-quarter profit on Tuesday helped by strong domestic demand, and said the U.S ...